Complementing the ICD effect, irinotecan also produces a cell stress response, resulting in PD-L1 expression; this allowed us to demonstrate synergistic boosting of the irinotecan-induced ICD response by anti-PD1 monoclonal antibodies in an orthotopic KRAS tumor model [13,16]. The gene discussed is KRAS; the disease is neoplasm.